Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Immune checkpoint Inhibitor-Induced Autoimmune Diabetes: Immunological Mechanisms and Biomarker Discovery in Provoked Beta Cell Autoimmunity

Award Number: K08AI193076
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 09/12/2025
PERIOD OF PERFORMANCE END DATE: 08/31/2030

Group Awards By:

View Award Description

Immune checkpoint Inhibitor-Induced Autoimmune Diabetes: Immunological Mechanisms and Biomarker Discovery in Provoked Beta Cell Autoimmunity - Project Summary/Abstract Within the last decade, immune checkpoint inhibitors (CPIs) have changed the landscape of cancer care, but also heightened risk for a range of endocrinopathies. While CPI treatment has led to tremendous benefits in a subset of cancers, they also have led to new-onset autoimmune disease (also known as “immune related adverse events” or “irAEs”) that can involve almost every organ. Within endocrine organs, insulin dependent autoimmune diabetes (CPI-DM) is highly morbid and potentially lethal. With this proposal Dr. Quandt plans a multipronged approach to address the mechanistic understandings of CPI-DM as examples of provoked autoimmunity. In Aim 1, Dr. Quandt will address genetic predisposition to CPI-DM. In Aim 2, Dr. Quandt will use an unbiased high throughput assay for novel autoantigen discovery to elucidate the specificity of the immune response in CPI-DM. In Aim 3, Dr. Quandt will use single cell methodologies to identify cellular phenotypes, activation, and differential gene expression contributing to a transcriptional signature critical to CPI-DM development. These studies will contribute to mechanistic understanding of CPI-DM with hope that they may lead to identification of actionable targets that could be used in the prevention or treatment of type 1 diabetes mellitus (T1DM), both in the setting of cancer immunotherapy and conventional disease. Dr. Quandt’s goal is to become a translational physician-scientist specializing in the immunology of T1DM and endocrine related aspects of cancer care, including endocrine irAEs. Bridging the divide between patient care and bench science is critical to furthering medical knowledge in both these novel and well-established autoimmune diseases. Dr. Quandt will advance her current experience in endocrinology, epidemiology and biostatistics through further training in wet lab approaches and bioinformatics including genetic analysis and computational immunology. This experience will anchor her understanding of translational methods to match her clinical research expertise. Her team of mentors, scientific advisors and collaborators are leaders in their respective fields. This training plan and scientific team will be coupled with the exceptional environment provided by the University of California, San Francisco, ensuring that Dr. Quandt will successfully advance to meet her career goal and transition to independence.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $200,587 )
2026	2026	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	2	8/11/2026	NON-COMPETING CONTINUATION	$200,587
														Subtotal = $200,587

Issue Date FY: 2025 ( Subtotal = $200,664 )
2025	2025	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	1	9/11/2025	NEW	$200,664
														Subtotal = $200,664

Grand Total All Awards = $401,251

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Immune checkpoint Inhibitor-Induced Autoimmune Diabetes: Immunological Mechanisms and Biomarker Discovery in Provoked Beta Cell Autoimmunity

Award Number: K08AI193076

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 09/12/2025

PERIOD OF PERFORMANCE END DATE: 08/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer